Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio®) Phase II Trial
- Written by PR Newswire
![]() |
- Positive primary endpoint result of objective response rate (ORR) from the planned interim analysis of Phase II trial in advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJ).
- Top-line data of the final analysis from Phase II to be announced in the second half of next year.
SEOUL, South Korea, May 19, 2023 /PRNewswire/ -- Genome &...















